| 1.22 -0.04 (-3.17%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.53 |
1-year : | 1.68 |
| Resists | First : | 1.31 |
Second : | 1.44 |
| Pivot price | 1.21  |
|||
| Supports | First : | 1.11 | Second : | 0.92 |
| MAs | MA(5) : | 1.25 |
MA(20) : | 1.2 |
| MA(100) : | 1.63 |
MA(250) : | 2.8 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 51.5 |
D(3) : | 57.2 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 6.75 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BBLG ] has closed below upper band by 48.0%. Bollinger Bands are 65.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.26 - 1.27 | 1.27 - 1.28 |
| Low: | 1.19 - 1.2 | 1.2 - 1.21 |
| Close: | 1.21 - 1.22 | 1.22 - 1.23 |
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. It is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. The company's platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. The company was founded in 2004 and is headquartered in Burlington, Massachusetts.
Sat, 14 Mar 2026
Bone Biologics Corporation Announces $1 Million At-the-Market Offering of Common Stock Through H.C. Wainwright & Co - Minichart
Fri, 13 Mar 2026
Bone Biologics launches $1.06 million at-the-market offering on Nasdaq - Investing.com
Tue, 03 Mar 2026
BBLG: Annual Report Shows Company Well Positioned - Smartkarma
Mon, 02 Mar 2026
Bone Biologics 10-K: Operating loss $3.23M, net loss $3.11M; EPS impact noted - TradingView
Tue, 23 Dec 2025
Bone-healing treatment in development now lasts 2 years on the shelf in tests - Stock Titan
Thu, 04 Sep 2025
Bone Biologics CEO Issues Letter to Stockholders Highlighting Company Update and Outlook - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 2.8 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 41 (K) |
| EPS | -2.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.34 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.7 % |
| Return on Equity (ttm) | -80.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|